Genetic and environmental regulation of caudate nucleus transcriptome: insight into schizophrenia risk and the dopamine system

Competing Interest Statement

The following BrainSeq Consortium members have competing interests. M.M., T.S., K.T., D.J.H. are employees of ARIA. D.A.C. and B.B.M. are employees of Eli Lilly and Company. K.M. is an employee of UCB Pharma and past employee of Eli Lilly and Company. M.F., D.H., and H.K. are employees of Janssen Research & Development LLC and Johnson and Johnson. M.D. and L.F. are employees of H. Lundbeck A/S. T.K.-T., and D.M. are employees of F. Hoffmann-La Roche.

Funding Statement

Funding sources: NIH T32MH015330, awarded to Kynon Benjamin; Brain and Behavior Research Foundation, NARSAD Young Investigator awarded to Jennifer Erwin; Lieber Institute for Brain Development; BrainSeq Consortium

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Human postmortem brain tissue was collected at several sites for this study. A large number of postmortem human brain samples were procured by the Clinical Brain Disorders Branch of the National Institute of Mental Health in collaboration with the Northern Virginia and District of Columbia Medical Examiners' Offices, under the auspices of a protocol approved by the Institutional Review Board of the National Institutes of Health (Protocol #90-M-0142). These samples were transferred to the Lieber Institute for Brain Development (LIBD) under a Material Transfer Agreement (MTA) with the NIMH. Additional samples were collected at the LIBD according to a protocol approved by the Institutional Review Board of the State of Maryland Department of Health and Mental Hygiene (#12-24) and the Western Institutional Review Board (#20111080). Additional fetal, child, and adolescent brain tissue samples were provided by the National Institute of Child Health and Human Development Brain and Tissue Bank for Developmental Disorders via MTAs (NO1-HD-4-3368 and NO1-HD-4-3383) approved by Institutional Review Board of the University of Maryland. Audiotaped informed consent to study brain tissue was obtained from the legal next-of-kin on every case collected at NIMH and LIBD. Details of the donation process and specimens handling are described previously (49). After next-of-kin provided audiotaped informed consent to brain donation, a standardized 36-item telephone screening interview was conducted, (the Lieber Institute for Brain Development Autopsy Questionnaire), to gather additional demographic, clinical, psychiatric history, substance abuse history, treatment, medical, and social history. A psychiatric narrative summary was written for every donor, to include data from multiple sources, including the Autopsy Questionnaire, medical examiner documents (investigative reports, autopsy reports, and toxicology testing), macroscopic and microscopic neuropathological examinations of the brain, as well as extensive psychiatric, detoxification, and medical record reviews, and/or supplemental family informant interviews using the MINI (Mini International Neuropsychiatric Interview). Two board-certified psychiatrists independently reviewed every case to arrive at a retrospective DSM-5 lifetime psychiatric and substance use disorder diagnoses, including schizophrenia and bipolar disorder, as well as substance abuse disorders. When consensus diagnosis was not reached between the two reviewers, a third board-certified psychiatrist was consulted. All donors were free from significant neuropathology, including cerebrovascular accidents and neurodegenerative diseases. Available postmortem samples were selected based on RNA quality (RNA integrity number ≥ 5). A toxicological analysis was performed in each case. The non-psychiatric non-neurological controls had no known history of significant psychiatric or neurological illnesses, including substance abuse. Positive toxicology was exclusionary for control subjects but not for patients with psychiatric disorders.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes